Literature DB >> 6187859

Independent immunodominant and immunorecessive tumor-specific antigens on a malignant tumor: antigenic dissection with cytolytic T cell clones.

R D Wortzel, J L Urban, C Philipps, F W Fitch, H Schreiber.   

Abstract

We have analyzed the complexity of a unique tumor-specific transplantation antigen expressed by the murine ultraviolet light-induced fibrosarcoma 1591-RE. This tumor is highly immunogenic and is regularly rejected by normal mice. We have derived a cloned cytolytic T cell line showing a reactivity pattern representative of the cytolytic response of the host rejecting this regressor tumor. Using this T cell line (anti-A), variants of 1591-RE (1591-A-) were selected in vitro that had lost the same antigen as progressor variants of 1591-RE selected by the host in vivo. The in vitro derived variant was then used to generate a second T cell clone (anti-B) that recognized an antigen on the parental tumor that had been retained by the variants derived in vitro. Host-selected progressor variants were also found to have retained this antigen. By selecting for variants in vitro from the parental tumor with the anti-B T cell line, it was shown that the two different antigens (A and B) present on the parental tumor were lost independently of each other. Despite the independence of these two antigens, the host T cell response to the parental regressor tumor was invariably restricted to only the "immunodominant" A antigen.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6187859

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Immunoselection of structural H-2Kb variants: use of cloned cytolytic T cells to select for loss of a CTL-defined allodeterminant.

Authors:  J M Sheil; M J Bevan; L A Sherman
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

2.  Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.

Authors:  Jay Friedman; Ellen C Moore; Paul Zolkind; Yvette Robbins; Paul E Clavijo; Lilian Sun; Sarah Greene; Megan V Morisada; Wojciech K Mydlarz; Nicole Schmitt; James W Hodge; Hans Schreiber; Carter Van Waes; Ravindra Uppaluri; Clint Allen
Journal:  Clin Cancer Res       Date:  2019-10-23       Impact factor: 12.531

Review 3.  Specificity in cancer immunotherapy.

Authors:  Andrea Schietinger; Mary Philip; Hans Schreiber
Journal:  Semin Immunol       Date:  2008-08-05       Impact factor: 11.130

4.  Malignant growth in the normal host after variant selection in vitro with cytolytic T-cell lines.

Authors:  R D Wortzel; J L Urban; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

5.  A murine plasmacytoma MOPC 104E resistant to cyclophosphamide is resistant to immunotherapy.

Authors:  K Satoh; N Kan; T Okino; M Nakanishi; K Mise; Y Teramura; S Yamasaki; K Ohgaki; T Tobe
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Tumor growth and evasion of immune destruction: UV-induced tumors as a model.

Authors:  C A Mullen; H Schreiber
Journal:  Surv Immunol Res       Date:  1985

Review 7.  Antibody phage display libraries: contributions to oncology.

Authors:  Carmela Dantas-Barbosa; Marcelo De Macedo Brigido; Andrea Queiroz Maranhao
Journal:  Int J Mol Sci       Date:  2012-05-04       Impact factor: 6.208

8.  Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells.

Authors:  P L Ward; H Koeppen; T Hurteau; H Schreiber
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

Review 9.  Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting.

Authors:  Fabio Nicolini; Martine Bocchini; Davide Angeli; Giuseppe Bronte; Angelo Delmonte; Lucio Crinò; Massimiliano Mazza
Journal:  Cancers (Basel)       Date:  2020-04-08       Impact factor: 6.639

10.  Highly malignant tumor variants retain tumor-specific antigens recognized by T helper cells.

Authors:  C Van Waes; J L Urban; J L Rothstein; P L Ward; H Schreiber
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.